GET DAILY SIGNALSAzora Therapeutics (AZR) Eyes $10 Target With +185% Potential Upside
Key Takeaways
- The central target of $10 is the arithmetic mean of three verified analyst price targets ($14, $11 and $6), rounded from an underlying $10.33.
- With shares recently trading near $3.51, reaching $10 would require an upside of roughly 185% — a very large move for any stock.
- Analyst targets span a wide $6 to $14 range, reflecting genuine disagreement about how much AT177 is worth before clinical proof.
- All three covering analysts rate the stock Buy or Strong Buy; none assign a Hold or Sell rating.
- Key supports are the AT177 program, a Phase 1 trial expected to begin in the first half of 2027, and a cash position sufficient for near-term development.
- Key risks are a pre-revenue model, widening losses, negative stockholders' equity, Nasdaq compliance pressure, and potential dilution.
- For more context on this company, explore its Major News, Today's Price Move, Forecast, and Earnings pages.
- Readers can also explore Trending AI Robots for automated trading ideas across the market.
Analyst Price Targets and Consensus View
Three current, individually attributable analyst price targets were reviewed for the AZR stock forecast. JonesTrading initiated coverage with a Buy rating and a $14 target in early November 2026, describing the aryl hydrocarbon receptor as a "reasonably derisked, but undervalued" inflammatory bowel disease target. Alliance Global Partners initiated with a Buy and an $11 target in August 2026, while Lucid Capital initiated with a Buy and a $6 target in June 2026.
The average analyst price target across these three figures is approximately $10.33, rounded to a $10 central target. The wide $6-to-$14 spread is notable: it reflects a fundamental disagreement about the probability-weighted value of AT177, which has not yet produced human efficacy data. The analyst consensus leans clearly bullish, but the dispersion underscores that this is a high-risk, high-reward development story rather than a de-risked revenue generator. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
AZR shares recently closed around $3.51, meaning the stock would need to appreciate by roughly 185% to reach the $10 level. That magnitude qualifies as a very large move. The path toward the target runs almost entirely through clinical execution: initiation of the Phase 1 trial for AT177, clean tolerability and dosing data, and eventually signals of efficacy in ulcerative colitis and Crohn's disease. Because the company is pre-revenue, the stock's market outlook is driven by binary scientific milestones and financing events rather than quarterly sales or earnings beats.
What Could Support a Move Toward the Target
The central bull case rests on AT177's mechanism. Aryl hydrocarbon receptor modulation is a biologically validated approach in inflammatory bowel disease, and an oral, gut-restricted formulation could offer a differentiated safety and convenience profile. A well-run Phase 1 initiation in the first half of 2027, encouraging biomarker or safety readouts, and additional analyst initiations or target increases could all support the stock price. A cash position reported near $28 million provides a near-term runway, and the company carries essentially no debt, limiting interest-rate exposure.
What Could Prevent the Target From Being Reached
The risks are substantial. Azora generates no revenue and its trailing net loss widened sharply to roughly $58 million, reflecting non-cash accounting items tied to warrants in addition to development spending. Stockholders' equity has turned deeply negative, and the company has faced Nasdaq minimum-equity compliance notices. A clinical setback, slower-than-expected enrollment, or a dilutive financing round could pressure the share price. In the absence of clinical data, the $10 target remains an aspiration tied to future proof rather than current fundamentals.
Technical Levels and Market Structure
AZR has traded in a broad range of roughly $1.31 to $8.75 over the past year, a span that includes its history under the prior Adial listing. More recently, shares have been below the 50-day moving average near $4.69 and the 100-day average near $3.98, while remaining above the 200-day average near $3.22. The $5 area has acted as a notable resistance level following the October rebrand, while the $3 level appears to be a psychological support level. The $10 target sits well above these established trading ranges, so a sustained breakout beyond prior highs would likely be required before the target becomes technically plausible. From what I see, Tickeron’s AI Trend Prediction Engine offers useful context on these patterns.
Time Horizon and What Investors Should Monitor
Analyst price targets for small-cap biotechs typically reflect a research horizon of around 12 months, though the individual firms here have not published identical timeframes and some targets are more event-driven than calendar-based. Investors should monitor the initiation and progress of the AT177 Phase 1 trial, any additional financing or partnership announcements, Nasdaq listing compliance updates, and any analyst target or rating changes. Quarterly cash-burn figures and dilution signals will also be important given the company's pre-revenue status. I’m watching this closely with the help of Tickeron’s AI Real Time Patterns for timely alerts.
Leveraging AI Daily Buy/Sell Signals for Monitoring
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, news-sensitive name like AZR, this type of automated monitoring can help traders spot shifting trends and manage positions more efficiently than manual chart-watching alone. Traders can use the signals to discover opportunities, track existing holdings, and react to emerging momentum with greater discipline. In my view, this tool has become a practical part of staying on top of names in this space without constant manual review.
Final Assessment
The $10 central target represents the average of three analyst price targets spanning $6 to $14, and it implies a roughly 185% gain from a recent price near $3.51 — a very large move. The bull case hinges on AT177, an oral AhR agonist for ulcerative colitis entering Phase 1 development in the first half of 2027, backed by a solid cash position and no debt. The bear case rests on a pre-revenue profile, widening losses, negative equity, Nasdaq compliance risk, and the absence of any clinical data. Analyst disagreement is wide precisely because the stock's value is binary at this stage. Investors should watch clinical progress, financing, and listing-compliance developments before drawing any conclusions about whether AZR can reach $10.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AZR saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for AZR moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 30 similar instances where the indicator exited the overbought zone. In 29 of the 30 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AZR as a result. In 88 of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for AZR turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 37 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
AZR moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AZR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
AZR broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AZR entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AZR's RSI Oscillator exited the oversold zone, 24 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
Following a +8.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where AZR advanced for three days, in 156 of 206 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.386) is normal, around the industry mean (3.498). P/E Ratio (-0.285) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. AZR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AZR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of medications to treat addiction and related disorders
Industry Biotechnology
Advertisement